

**SILAKin: A novel high throughput SILAC and mass spectrometry-based assay
to identify the substratome of kinases secreted by pathogens**

Despina Smirlis^{1,2}, Florent Dingli³, Valentin Sabatet³, Aileen Roth⁴, Uwe Knippchild⁴, Damarys Loew³, Gerald F. Späth¹, Najma Rachidi^{1*}

¹Institut Pasteur and Institut National de Santé et Recherche Médicale INSERM U1201, Unité de Parasitologie Moléculaire et Signalisation, Paris, France

²Hellenic Pasteur Institute, Athens, Greece.

³Laboratoire de Spectrométrie de Masse Protéomique (LSMP), Centre de Recherche, Institut Curie, PSL Research University, Paris, France

⁴Department of General and Visceral Surgery, Centre of Surgery, University Hospital Ulm, ULM, Germany

Running Title: *Leishmania Casein Kinase I phosphorylates macrophage proteins.*

*To whom correspondence should be addressed: Najma Rachidi. Institut Pasteur and INSERM U1201, Unité de Parasitologie Moléculaire et Signalisation, Paris, France. Tel: +33144389231; Fax: +330145688332; E-mail: najma.rachidi@pasteur.fr

Keywords: Kinase, Casein kinase I, substrate screen, SILAC, host-pathogen interactions.

ABSTRACT

Protein phosphorylation is one of the most important reversible post-translational modifications. It affects every cellular process including differentiation, metabolism and cell cycle. Eukaryotic protein kinases (ePK) catalyse the transfer of a phosphate from ATP onto proteins, which regulates fast changes in protein activity, structure or subcellular localisation. The systematic identification of substrates is thus crucial to characterise the functions of kinases and determine the pathways they regulate, and even more so when studying the impact of pathogens-excreted kinases on the host cell signal transduction. Several strategies and approaches have been used to identify substrates, but all show important limitations thus calling for the development of new efficient and more convenient approaches for kinase substrate identification.

Herein, we present SILAkin, a novel and easy method to identify substrates that is applicable to most kinases. It combines phosphatase treatment, pulse heating, *in vitro* kinase assay (IVKA) and SILAC (Stable Isotope Labeling with Amino acids in Cell culture)-based quantitative mass spectrometry (MS). We developed SILAkin using the *Leishmania* casein kinase 1 (L-CK1.2) as experimental model. *Leishmania*, an intracellular parasite causing Leishmaniasis, releases L-CK1.2 in its host cell. Applying this novel assay allowed us to gain unprecedented insight into host-pathogen interactions through the identification of host substrates phosphorylated by pathogen-excreted kinases. We identified 225 substrates, including 85% previously unknown that represent novel mammalian CK1 targets, and defined a novel CK1 phosphorylation motif. The substratome was validated experimentally by L-CK1.2 and human CK1 δ , demonstrating the efficiency of SILAkin to identify new substrates and revealing novel regulatory pathways. Finally, SILAkin was instrumental in highlighting host pathways potentially regulated by L-CK1.2 in *Leishmania*-infected host cells, described by the GO terms ‘viral & symbiotic interaction’, ‘apoptosis’, ‘actin cytoskeleton organisation’, and ‘RNA processing and splicing’. SILAkin thus can generate important mechanistic insights into the signalling of host subversion by these parasites and other microbial pathogen adapted for intracellular survival.

INTRODUCTION

Protein phosphorylation, one of the essential reversible post-translational modifications, affects every cellular process including transport, metabolism and DNA repair [reviewed in ¹]. Eukaryotic protein kinases (ePK) catalyse the transfer of a phosphate from ATP onto proteins to regulate fast changes in protein activity, structure, interaction, or subcellular localisation. ePKs target proteins through kinase-specific recognition motif, which allows for specificity and restricts the number of their substrates. The systematic identification of substrates is thus crucial to characterise the functions of kinases and determine the pathways they regulate - even more so when studying the impact of pathogens-derived kinases on the host cell signal transduction during intracellular infection, for instance, by viral and bacterial pathogens ². However, the low stoichiometry of protein phosphorylation, the presence of endogenous kinases as well as the reversibility of the phosphorylation by phosphatases render systematic mapping of the cellular substratome extremely challenging. This is particularly true when handling pleiotropic signalling kinases such as casein kinase 1 (CK1), able to phosphorylate hundreds of substrates ³, or investigating pathogen-excreted kinases that are low in abundance and compete with high-abundant host kinases thus precluding the identification of *de novo* phosphorylation events by these exo-kinases.

Several strategies and approaches have been developed and applied to identify substrates (for review see ⁴), including (i) genetic screens ^{5, 6}, (ii) protein and peptide arrays ^{7, 8}, (iii) phage display ^{9, 10}, (iv) KinasE Substrate Tracking and ELucidation (KESTREL) ¹¹, (v) Kinase-Interacting Substrate Screening (KISS)¹², (vi) chemical-genetic methods with genetically engineered kinases ¹³ and (vii) quantitative phosphoproteomics in intact cells ^{14, 15}. Although these approaches allowed the identification of an important number of substrates, but all show important limitations, which include bottlenecks inherent to high-throughput mutagenesis in genetic screens; laborious process and low-throughput screening for KESTREL; unstable interactions for KISS or the low catalytic efficiency of certain engineered kinases for chemical-genetic screens. Thus there is an urgent need to develop new easy and efficient approaches for kinase substrate identification, especially since the most important human diseases such as cancer or neurodegenerative diseases are linked to deregulation, or mutations of kinases ¹⁶.

Here, we pioneered a novel technology, applicable to most protein kinases, termed SILAkin that allows for easy and efficient identification of substrates. Applied to intracellular macrophage infection with the protozoan pathogen *Leishmania*, we identified host substrates that shed important new light on parasite immune subversion and validate SILAkin as a powerful new tool to study mechanisms of host/pathogen interaction.

RESULTS

Background

Pathogens that invade mammalian host cells export proteins and particularly kinases via exosomes to modify their host cell^{17, 18}. Identification of host substrates for these exo-kinases could be particularly challenging, as only a small fraction of the kinase pool is exported, and exosomes represent a complex environment containing many proteins, including other kinases that could mask substrate phosphorylation by the kinase of interest (KOI). We thus developed a method to identify host substrates of pathogen kinases, irrespective of their abundance and the complexity of the environment. As a proof of principle, we identified the host substrates of L-CK1.2, released by *Leishmania* parasites^{18, 19}; since little is known about the pathways it regulates in macrophages. *Leishmania* is an intracellular parasite that resides in the parasitophorous vacuole of macrophages and subvert its host cell to survive.

Strategy and establishment of the experimental protocol

To identify the L-CK1.2 host-substratome, we implemented an experimental workflow designed to quantify phospho-peptide stoichiometry by LC/MS-MS, in metabolically-labelled, heat inactivated THP-1 macrophage protein lysates after their phosphorylation by recombinant L-CK1.2 (**Fig.1A**). Because CK1 recognises consensus sites that require or not priming by upstream kinases, prior *in vitro* kinase assay (IVKA), we depleted the lysates in ATP before treating them or not with Antarctic phosphatase. Dephosphorylation of existing phospho-sites increased the number of sites available for

de novo L-CK1.2 phosphorylation. Phospho-peptide stoichiometry was calculated from technical triplicate as a ratio of Heavy_{L-CK1.2}/Light_{L-CK1.2-K40A} and comparisons were made to phospho-peptide ratios of Heavy/Light mock reactions without kinases.

For establishing appropriate experimental conditions, several pilot experiments were carried out. To decrease the background activity of endogenous kinases, the lysate of THP-1 macrophages was pulse-heated to denature endogenous kinases (**Fig. S1**). Denaturation efficiency was demonstrated by the absence of ³²P incorporation in the background control (**Fig. S1, lane 2**). In contrast, the *de novo* phosphorylation of denatured THP-1 proteins by active L-CK1.2 was detected, showing that L-CK1.2 phosphorylates proteins present in the macrophage lysate (**Fig. S1, lane 1**). To increase the number of sites available for *de novo* phosphorylation in the macrophage lysate, two steps were added to the pipeline (**Fig. 1A**). Free ATP was depleted from protein lysates by dialysis to prevent any phosphorylation while the samples were dephosphorylated by Antarctic phosphatase. The increase of ³²P incorporation into substrates following phosphatase treatment (**Figure S1, lane 3**) confirms that previously many sites were inaccessible to *de novo* phosphorylation. To reduce technical errors during sample preparation for MS, limit missing values and perform quantitative analyses, we used Stable Isotope Labelling with Amino acids in Cell culture (SILAC). This method relies on the metabolic incorporation of either “Heavy” [²H₄-Lysine (Lys⁴) and ¹³C₆-Arginine (Arg⁶)] or natural (“Light”) [lysine (Lys⁰) and arginine (Arg⁰)] amino acids ^{20, 21}. We validated by LC-MS/MS analysis the percentage of incorporation of Lys⁴ and Arg⁶ in macrophage proteins. This analysis revealed that more than 99 % of the identified peptides contained the two heavy amino acids. Finally, to reduce the risk of selecting false positive signals, we performed mock kinase assays using the “light” and “heavy” macrophage lysates without adding the kinases, to discard sites already differentially phosphorylated prior to the kinase assays.

Application of the pipeline for the identification of L-CK1.2 host cell substrates.

Three independent reactions for each condition were carried out, and two independent protein extracts treated or not with phosphatase were used. In the absence of phosphatase treatment, 7,752 unique

phosphopeptides belonging to 3,544 unique proteins were identified of which 65% were quantified (see **Fig.S2A&B** for Venn diagrams). The same analysis was performed with samples pre-treated with phosphatase, and 15,852 phosphopeptides (5,158 proteins) were identified of which 66% were quantified (**Fig.S2C&D**), demonstrating the efficiency of the phosphatase treatment. However, the increase in phospho-peptides also in the H/L control (**Fig.S2A&B**) suggests that the pulse-heating step did not completely abrogate but only reduced the activity of endogenous kinases to levels undetectable by autoradiography (**Fig.S1**).

To determine *L-CK1.2* substrates, the following selection criteria were applied: (i) A probability of correct localisation of the phosphorylation site on validated peptides greater than 75%, as calculated by PtmRS software (see Data analysis of Material & methods), (ii) the ratio Heavy_{L-CK1.2}/Light_{L-CK1.2-K40A} equal or above two to select the sites phosphorylated by L-CK1.2; and (iii) the ratio Heavy_{L-CK1.2}/Light_{L-CK1.2-K40A} at least twofold higher than that of the control Heavy/Light to only select the newly phosphorylated sites. Using the above criteria, 99 phosphopeptides (81 proteins) and 158 phosphopeptides (144 proteins) were selected as potential substrates of *L-CK1.2* in absence or in presence of phosphatase, respectively (**Table 1**). Only fifteen proteins were common to the two datasets. Although consistent with the stochasticity of the LC/MS analysis, this finding suggests that the phosphatase treatment greatly improves the access of L-CK1.2 to new substrates for which it has more affinity.

Validation of the SILAkin method

Three levels of validation were used to demonstrate that the dataset containing 225 proteins are bona fide host *L-CK1.2* substrates (**Table 2**). First, we identified 11 known human CK1 substrates, including the interferon-alpha/beta receptor alpha chain (IFNAR1)²², Sprouty 2 (SPRY2)²³ and Fam83H²⁴ as well as 66 known CK1 binding partners, which thus might also be substrates. Second, we showed that the phosphorylated peptides were highly enriched in known CK1 consensus sites²⁵. Hundred and twenty-six sites display the canonical CK1-phosphorylation motif, [S/T]X₂₋₃[pS/pT] or [E/D]X₂₋₃[pS/pT] (**Table 1, Fig. 1B top panel**), consistent with the affinity of CK1 for these two

motifs²⁶⁻³³. Seventy-four sites display the non-canonical consensus SLS-Xn-(E/D)n^{29, 34-36} or resemble to K/R(X)K/R(XX)**pS/pT**, a CK1 consensus site identified in cholesterol and sulfatide binding proteins (**Table 1, Fig. 1B middle panel**)³⁷. Surprisingly, this motif was present in only 10 phosphopeptides while the remaining 58 peptides contained a shorter version, K/R(XX)**pS/pT**. Finally, seventy-seven phospho-sites did not contain any known CK1 motif (others, **Table 1**), and might represent novel mammalian CK1 phosphorylation motif (**Table 1**). Indeed, we identified [G]XX[**pS/pT**] in 13 phospho-peptides (**Fig. 1B bottom panel and Table 3**). Noticeably, all the consensus sites identified in this study have a proline residue adjacent to the phosphorylated S or T, [**pS/pT**][P] (**Fig. 1B, position 7**), which was not described for other CK1s. In that, it resembles the phosphorylation motif phosphorylated by CDKs³⁸, and might be a characteristic of L-CK12 substrate recognition. Third, experimental validation of the phosphoproteomics analyses was carried out by the implementation of an *in vitro* kinase assay (IVKA) using purified human recombinant proteins, as substrates. We included five proteins that might be important for *Leishmania* intracellular survival based on their potential to modulate macrophage functions and/or inflammation. The selected recombinant proteins, namely reticulocalbin 2 (RCN2, Q14257), 14-3-3 γ (YWHAG, P61981), lactoylglutathione lyase 1 (Glo1, Q04760), synaptosomal-associated prot 23 (SNAP23, O00161) and transcription initiation factor TFIID subunit 7 (TAF7, Q15545) were subjected to a kinase assay using inactive L-CK1.2-K40A (kinase-dead), active L-CK1.2 alone or in presence of the CK1-specific small molecule inhibitor D4476³⁹. All recombinant proteins were phosphorylated by L-CK1.2, but no phosphorylation was observed in the D4476 and L-CK1.2-K40A controls (**Fig. 1C**). All L-CK1.2 substrates tested were also phosphorylated by CK1 δ , confirming the relevance of our substratome for human CK1s (**Fig. 1D**). Altogether, these results confirm that our dataset identified bona fide L-CK1.2 host cell substrates, which validate the SILAkin method. Furthermore these substrates are potentially also targeted by human CK1 δ , revealing novel targets and thus new pathways regulated by human CK1 δ .

Physiological relevance of L-CK1.2 substrates for human diseases.

Because SILAkin is an *in vitro* method, the question of physiological relevance needed to be addressed. To this end, our dataset was compared to human cell phospho-proteomes to determine whether any of the 257 phospho-sites were phosphorylated *in vivo*. 94% were identified in various phospho-proteomes (**Table 1 and S1**, <https://www.phosphosite.org/homeAction.action>), suggesting that the phospho-sites identified by SILAkin are physiologically relevant. Our data allow the attribution of those sites to human CK1. Similarly, we investigated whether any L-CK1.2 substrates were described as differentially regulated in human diseases. Indeed, 89% of phospho-sites are phosphorylated in cancer cells (**Table 1&S1 and Fig.2, round shape**) and 10% are mutated during tumorigenesis (**Table 1&S1 and Fig.2, red border**). Moreover, 76% of the L-CK1.2 substrates are considered as prognosis markers for various cancer types (**Table 1&S1**). These data are consistent with the fact that human CK1 isoforms are overexpressed in cancer cells^{25, 40} and often contribute to chemo- and apoptosis resistance as well as to a reduction of overall survival of patients²⁵. Regarding infectious diseases, we showed that 51% of L-CK1.2 substrates are phosphorylated during SARS-CoV2 infection (**Fig. 2, green**), and 20% on the same sites as those phosphorylated by L-CK1.2 (**Table 1&S1**). Surprisingly, only two GO processes are enriched, ‘RNA splicing’ and ‘cellular localisation and transport’ in the substrates phosphorylated by L-CK1.2 and SARS-CoV2 infection (**Fig. S3 and Table S2&S3**), suggesting that SARS-CoV2 and *Leishmania* might similarly exploit these two processes and that SARS-CoV2 might exploit CK1 pathways for its replication. Our data demonstrate the potential impact of CK1 in SARS-CoV2 infection, which is consistent with the role of host CK1 in viral replication^{41 42-44}.

Enriched pathways and relevance for Leishmania infection

Although obtained *in vitro*, the substratome is enriched in proteins physiologically relevant for *Leishmania* infection (60% total) and might give us important insights into the mechanisms developed by *Leishmania* to subvert its host cell. Indeed, during *Leishmania* infection, 32% of L-CK1.2 substrates were shown to be differentially regulated at protein level⁴⁵⁻⁴⁸, while 30% were differentially expressed at transcript level⁴⁹⁻⁵² (**Table 1**). In the substratome, we identified functional enrichment for GO terms relative to apoptosis or RNA processing and splicing, which is consistent with *Leishmania*

inhibiting host apoptosis^{53, 54} or modifying the host transcriptome, respectively^{49, 55} (**Fig. 3**). Moreover, several key processes, preferentially targeted by *Leishmania* CK1.2, are associated with host-pathogen interactions such as ‘viral and symbiotic interaction’ or ‘cellular response stimulus’ (**Fig. 3, Table S4**). Lastly, the identification of processes such as ‘positive regulation of metabolic process’, ‘positive regulation of molecular function activity’ and ‘GTPase signal transduction’, are consistent with L-CK1.2 being a signalling kinase (**Fig. 3, Table S4**). Altogether, its functional characterisation supports the physiological relevance of the substratome, while revealing the pathways that might be regulated by L-CK1.2 during *Leishmania* infection. These pathways should be investigated in priority to decipher L-CK1.2 functions in the host cell.

DISCUSSION

Increasing the knowledge on kinases and particularly the pathways they regulate is crucial to better understand cellular functions, hence the importance of finding their substrates in an unbiased manner. It is even more important when studying host cell signalling pathways exploited by pathogens during infection through the release of their kinases. Many high throughput methods exist and most of them have important drawbacks or are not adapted to host-pathogen interaction studies⁵⁶. Here, we propose SILAkin, a novel, easy, and validated method applicable to most kinases from any organism that overcomes most of the limitations existing in other mass spectrometry-based methods: First, it allows direct detection of phosphorylation, contrary to phospho-proteomics comparing WT and mutant kinase⁴. Second, it does not require the modification of the kinase, thus avoiding potential artifacts observed in chemical-genetic methods¹³. Finally, ATP depletion and phosphatase treatment were particularly efficient to reveal novel and previously inaccessible phospho-sites. Our method has two main limitations. First, the variability of mass spectrometry analyses, thus increasing the number of replicate will increase the depth of identification and consequently the number of substrate identified. Second, limitations inherent to *In vitro* kinase assays such as non-physiological kinase regulation, sub-optimal production of an active recombinant kinase or *in vivo* substrate accessibility, thus *in vivo* validation of the dataset will be required. Because L-CK1.2 is constitutively active, accesses all cellular

compartments^{39, 57}, and recognises specific consensus sites, the limitations inherent to IVKA do not apply. L-CK1.2 is therefore the perfect kinase to demonstrate the efficiency of SILAkin.

Our large dataset allowed us to refine existing CK1 substrate recognition motif such as K/R(X)K/R(XX)**pS/pT**, for which we proposed a shorter version, K/R(XX)**pS/pT**³⁷; and to define a novel CK1 consensus site such as [G]X₂₋₃[**pS/pT**], validated experimentally with L-CK1.2 and CK1δ (SNAP23, **Fig. 1C and D**). Further analyses, including mutagenesis, will be required to confirm this new consensus, as we cannot exclude the possibility that SNAP23 was phosphorylated on another site. Surprisingly, we identified a proline residue adjacent to the phosphorylated S/T ([**pS/pT**][P]), its requirement remains to be confirmed experimentally and might only applied to *Leishmania* CK1.2, since it was not described for other CK1 orthologs.

Finally, this study identified 225 CK1 substrates, including 214 previously unknown. Many substrates have a link with human diseases, including cancer, SARS-CoV2⁵⁸ or *Leishmania* infections^{46-48, 59}, suggesting that the corresponding pathways might be regulated by CK1. These findings are consistent with human CK1 having cancer-associated functions linked to its involvement in the Wnt (Wingless/Int-1), Hh (Hedgehog), and Hippo signalling pathways^{3, 25}, or with the involvement of CK1 in infectious diseases⁶⁰⁻⁶³. Applied to *Leishmania* parasites, this study by revealing the potential pathways regulated by L-CK1.2 in macrophages, such as ‘viral & symbiotic interaction’, ‘actin cytoskeleton organisation’⁶⁴, and ‘RNA processing and splicing’^{49, 55}, proposes mechanistic insights into the signalling of host subversion by *Leishmania*.

In conclusion, we developed a method sufficiently sensitive to reveal substrates phosphorylated by pathogen-excreted kinases, allowing us to gain insights into host-pathogen interactions.

MATERIALS & METHODS

SILAC labelling and lysate preparation

For labelling cells by SILAC, equal numbers of THP-1 monocytes ($2 \times 10^5 \text{ ml}^{-1}$) were seeded in RPMI 1640 without Lysine and Arginine (Thermo Fisher Scientific), supplemented either with natural amino acids (L-Lysine, 0.274 mM; L-Lysine, 1.15 mM; Arginine, 1.15 mM) or with the same concentrations

of amino acid isotopes 2H_4 -Lysine (Lys4) and $^{13}\text{C}_6$ --Arginine (Arg6) (Thermo Scientific). The medium was supplemented with $50\ \mu\text{M}$ β -mercaptoethanol, $50\ \text{U mL}^{-1}$ penicillin, $50\ \mu\text{g mL}^{-1}$ streptomycin and 10% (v/v) of dialysed Fetal Bovine Serum (Sigma). Cells were split and seeded before reaching a concentration of $10^6\ \text{mL}^{-1}$ in fully supplemented SILAC medium, for a period of at least 15 days. 0.75 to 1×10^8 cells were then differentiated for 48 h into macrophages by the addition of $10\ \text{ng mL}^{-1}$ PMA. Cells cultivated in SILAC medium were washed three times in PBS and lysed in RIPA lysis and extraction buffer (Thermo Scientific) containing one tablet per 10 mL of cComplete™ Protease Inhibitor Cocktail tablets (Sigma). Cell extracts were incubated on ice 30 min, sonicated 5 min, and centrifuged 15 min at $14,000\ \text{g}$ to eliminate cell debris. Proteins were quantified in the supernatants using the RC DC™ protein assay kit (Bio-Rad), according to the manufacturer's instructions. For free ATP depletion, protein extracts were dialyzed overnight at 4°C in 1 liter of dialysis solution ($1 \times$ PBS, 1 mM EDTA, 1 mM dithiothreitol) in a Slide-A-Lyzer dialysis cassette (Pierce).

Expression and purification of L-CK1.2 and L-CK1.2-K40A

Bacterial expression plasmid for L-CK1.2 was generated as previously described⁶². Bacterial expression plasmid carrying L-CK1.2-K40A (kinase dead) was generated by site directed mutagenesis as previously reported⁶². Recombinant proteins were induced in Rosetta™ (DE3) Competent Cells (Novagen) with 0.02% (w/v) L-arabinose for 3 h at $25\ ^\circ\text{C}$. Cells were harvested and resuspended in lysis buffer as previously described⁶². Briefly recombinant kinases were purified on co-nitrilotriacetic acid agarose (Pierce) and eluted in 300 mM imidazole in PBS containing 60 mM β -glycerophosphate, 1 mM sodium vanadate, 1 mM sodium fluoride and 1 mM disodium phenylphosphate. Protein eluates were supplemented with 15% glycerol and stored at -80°C .

Protein kinase assay and phosphatase treatment. For phosphatase treatment, 500 μg of “heavy” or “light” THP-1 protein extract were dephosphorylated with 50 U of Antarctic phosphatase (NEB) in Antarctic phosphatase buffer (NEB) for 30 min at $37\ ^\circ\text{C}$. Phosphatase activity was heat inactivated at 65°C for 15 min. The kinase assay for the “heavy” or “light” protein extracts (500 μg) were performed in buffer C (60 mM β -glycerophosphate, 30 mM *p*-nitrophenyl phosphate, 25 mM MOPS

[morpholinepropanesulfonic acid], 5 mM EGTA, 15 mM MgCl₂, 1 mM dithiothreitol, 0.1 mM sodium vanadate; pH 7.0) in the presence of 15 μM ATP and 200 ng of recombinant L-CK1.2 or kinase dead L-CK1.2-K40A. The reaction was performed in triplicate at 30°C for 45 min. For mock reactions no kinases were added. Reactions were stopped with the addition of 10 μM of D4476 {4- [4-(2,3-dihydro-1,4- benzodioxin-6-yl)- 5- 2-pyridinyl)- 1*H*- imidazol-2-yl]} benzamide, a specific inhibitor of CK1 known to inhibit *L-CK1.2* activity⁶⁵, followed by heat inactivation at 65°C for 15 min. Next, kinase inactivation heavy and light protein samples were mixed in a 1:1 ratio, and precipitated in 80 (v/v) % ice-cold acetone and stored at -80°C prior to LC/MS-MS analysis. For IVKA with L-CK1.2, 15 μg of total THP-1 protein extracts or 0.5 to 1.0 μg of recombinant proteins, GST-14-3-3γ (Enzo #BML-SE313-0100), RCN2-6XHis (Abcam #ab125644) Glo1 (Abcam # ab206792), SNAP23 (Abnova #H00008773-P01) and TAF7 (Abnova #H00006879-P01), were assayed with 0.2 μg of L-CK1.2 or L-CK1.2-K40A, as described in Rachidi *et al.*³⁹. Incorporated ³²P was monitored by SDS-PAGE and autoradiography. For IVKA with human GST-CK1δ^{TV1}, 6 ng of kinase was incubated with the 0.5 to 1.0 μg of recombinant proteins (see above) in 1x kinase buffer (250mM tris-HCL pH 7.0, 100 mM MgCl₂, 1mM EDTA) and 15μM ³²P-γATP in 30μL final volume for 30 min at 30°C. All kinase assays were performed at least three times.

Phospho-peptide enrichment.

Phosphorylated peptides were enriched using TitansphereTM Phos-TiO kit centrifuge columns (3mg/200μL, cat. No. 5010-21312, GL Sciences), as described by the manufacturer. After elution from the Spin tips, phospho-peptides were vacuum concentrated to dryness and reconstituted in 0.1% formic acid. Samples were then loaded onto a custom-made C18 StageTips for desalting. Enriched phosphor-peptides were eluted using 40/60 MeCN/H₂O + 0.1% formic acid and vacuum concentrated to dryness.

Liquid chromatography-tandem mass spectrometry.

LC was performed with an RSLC nano system (Ultimate 3000, Thermo Scientific) coupled online to an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific). Peptides were first trapped on a C18 column (75 μm inner diameter × 2 cm; nanoViper Acclaim PepMapTM 100, Thermo Scientific) with buffer A (2/98 MeCN/H₂O in 0.1% formic acid) at a flow rate of 2.5 μL/min over 4 min.

Separation was then performed on a 50 cm x 75 μ m C18 column (nanoViper Acclaim PepMapTM RSLC, 2 μ m, 100 \AA , Thermo Scientific) regulated to a temperature of 55°C with a linear gradient of 2% to 25% buffer B (100% MeCN in 0.1% formic acid) at a flow rate of 350 nL/min over 211 min. Separation of phospho-peptide samples without phosphatase, was performed with buffer A' (5/98 DMSO/H₂O in 0.1% formic acid) and B' (5/95 DMSO/MeCN in 0.1% formic acid) by using a linear gradient of 2% to 30% with the same time and flow rate as previous gradient. Full-scan MS was acquired in the Orbitrap analyzer with a resolution set to 240,000, a mass range of m/z 400-1500 and a 4×10^5 ion count target. Ions from each full scan were HCD fragmented with normalized collision energy of 30 % and rapid scan MS analysed in the linear ion trap. The MS² ion count target was set to 2×10^4 and only those precursors with charge state from 2 to 7 were sampled for MS² acquisition.

Data analysis. For identification, the data were searched against the Homo sapiens (UP000005640) UniProt database using Sequest-HT through Proteome Discoverer (PD, version 2.4). Enzyme specificity was set to trypsin and a maximum of two-missed cleavage sites was allowed. Oxidized methionine, Met-loss, Met-loss-Acetyl, Ser/Thr/Tyr phosphorylation, N-terminal acetylation, heavy ²H₄-Lysine (Lys4) and ¹³C₆-Arginine (Arg6) were set as variable modifications. Carbamidomethyl of Cysteines were set as fixed modification. Maximum allowed mass deviation was set to 10 ppm for monoisotopic precursor ions and 0.6 Da for MS/MS peaks. The resulting files were further processed using myProMS v3.9.2⁶⁶. The Sequest-HT target and decoy search result were validated at 1% false discovery rate (FDR) with Percolator at the peptide level. Technical replicates (n=3) were merged using the MSF files node and a SILAC-based phospho-peptides quantification was performed by computing peptides XICs (Extracted Ion Chromatograms). The phospho-site localization accuracy was estimated by using the PtmRS node in PD (version 2.4), in PhosphoRS mode only. Phospho-sites with a localization site probability greater than 75% and with at least two SILAC measurements per peptide were quantified at the peptide level. Mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE⁶⁷ partner repository with the dataset identifier PXD.

Motif discovery.

Unique phospho-peptides sequences, matching the strict selection criteria, were aligned on phosphorylated serine and threonine with 5 flanking amino acids. PhosphoSitePlus phosphosite plus

(<https://www.phosphosite.org/homeAction.action>⁶⁸), was used to compute motif analysis enrichment (automatic background selection; significance of 1e-6; support threshold of 0.1) and to generate corresponding sequence logo (automatic background selection; frequency change algorithm⁶⁹).

STRING network visualization and gene ontology enrichment analysis

The dataset was analyzed for protein-protein interactions and visualized using the STRING plugin (string, <https://string-db.org/>⁷⁰) of the Cytoscape software package (version 3.8.2, <https://cytoscape.org/>⁷¹). Each node represents a substrate and each edge represents a protein-protein interaction. Functional enrichment analysis of the dataset was performed using the g:profiler web server (<https://biit.cs.ut.ee/gprofiler/gost>) using the following criteria: only annotated genes, with a significance threshold of 0.05, select GO terms of less than 5 000 genes, and only focusing on GO 'biological process'. Results were visualized using the EnrichmentMap plugin of the Cytoscape software package (version 3.3, <http://apps.cytoscape.org/apps/enrichmentmap>⁷²), with a p-value and a Q-value above 0.05 and an edge cut-off of 0.375. Node color represents the enrichment p-value (see legend Figure 2). Node size is proportional to the total number of genes belonging to the corresponding gene-set. The edge corresponds to the Annotation shared between two nodes, with edge thickness corresponding to the number of shared genes. Node clusters were identified and annotated by the AutoAnnotate plugin of cytoscape (version 1.3.3 <https://autoannotate.readthedocs.io/en/latest/>).

REFERENCES

1. Ardito, F., Giuliani, M., Perrone, D., Troiano, G. & Lo Muzio, L. The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review). *Int J Mol Med* **40**, 271-280 (2017).
2. Alto, N.M. & Orth, K. Subversion of cell signaling by pathogens. *Cold Spring Harbor perspectives in biology* **4**, a006114 (2012).
3. Knippschild, U. et al. The CK1 Family: Contribution to Cellular Stress Response and Its Role in Carcinogenesis. *Frontiers in oncology* **4**, 96 (2014).
4. Xue, L. & Tao, W.A. Current technologies to identify protein kinase substrates in high throughput. *Frontiers in biology* **8**, 216-227 (2013).
5. Paradis, S. & Ruvkun, G. Caenorhabditis elegans Akt/PKB transduces insulin receptor-like signals from AGE-1 PI3 kinase to the DAF-16 transcription factor. *Genes Dev* **12**, 2488-2498 (1998).
6. Sopko, R. et al. Mapping pathways and phenotypes by systematic gene overexpression. *Molecular cell* **21**, 319-330 (2006).
7. Ptacek, J. et al. Global analysis of protein phosphorylation in yeast. *Nature* **438**, 679-684 (2005).

8. Schutkowski, M., Reineke, U. & Reimer, U. Peptide arrays for kinase profiling. *Chembiochem* **6**, 513-521 (2005).
9. Fukunaga, R. & Hunter, T. MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. *EMBO J* **16**, 1921-1933 (1997).
10. Schmitz, R., Baumann, G. & Gram, H. Catalytic specificity of phosphotyrosine kinases Blk, Lyn, c-Src and Syk as assessed by phage display. *J Mol Biol* **260**, 664-677 (1996).
11. Cohen, P. & Knebel, A. KESTREL: a powerful method for identifying the physiological substrates of protein kinases. *Biochem J* **393**, 1-6 (2006).
12. Amano, M. et al. Kinase-interacting substrate screening is a novel method to identify kinase substrates. *The Journal of cell biology* **209**, 895-912 (2015).
13. Shah, K., Liu, Y., Deirmengian, C. & Shokat, K.M. Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates. *Proceedings of the National Academy of Sciences of the United States of America* **94**, 3565-3570 (1997).
14. Batista, M. et al. The MAP kinase MAPK11 is essential to *Trypanosoma brucei* proliferation and regulates proteins involved in mRNA metabolism. *J Proteomics* **154**, 118-127 (2017).
15. Shinde, M.Y. et al. Phosphoproteomics reveals that glycogen synthase kinase-3 phosphorylates multiple splicing factors and is associated with alternative splicing. *J Biol Chem* **292**, 18240-18255 (2017).
16. Lahiry, P., Torkamani, A., Schork, N.J. & Hegele, R.A. Kinase mutations in human disease: interpreting genotype-phenotype relationships. *Nature reviews. Genetics* **11**, 60-74 (2010).
17. Ofir-Birin, Y. & Regev-Rudzki, N. Extracellular vesicles in parasite survival. *Science* **363**, 817-818 (2019).
18. Silverman, J.M. et al. Leishmania exosomes modulate innate and adaptive immune responses through effects on monocytes and dendritic cells. *J Immunol* **185**, 5011-5022 (2011).
19. Silverman, J.M. et al. An exosome-based secretion pathway is responsible for protein export from *Leishmania* and communication with macrophages. *J Cell Sci* **123**, 842-852 (2010).
20. Basken, J. et al. Specificity of phosphorylation responses to MAP kinase pathway inhibitors in melanoma cells. *Mol Cell Proteomics* (2017).
21. Polat, A.N. et al. Phosphoproteomic Analysis of Aurora Kinase Inhibition in Monopolar Cytokinesis. *J Proteome Res* **14**, 4087-4098 (2015).
22. Liu, J. et al. Mammalian casein kinase 1 α and its leishmanial ortholog regulate stability of IFNAR1 and Type I interferon signaling. *Mol Cell Biol* **29**, 6401-6412 (2009).
23. Yim, D.G., Ghosh, S., Guy, G.R. & Virshup, D.M. Casein kinase 1 regulates Sprouty2 in FGF-ERK signaling. *Oncogene* **34**, 474-484 (2015).
24. Fulcher, L.J. et al. The DUF1669 domain of FAM83 family proteins anchor casein kinase 1 isoforms. *Science signaling* **11** (2018).
25. Xu, P. et al. Structure, regulation, and (patho-)physiological functions of the stress-induced protein kinase CK1 δ (CSNK1D). *Gene* **715**, 144005 (2019).
26. Donella-Deana, A. et al. A type-1 casein kinase from yeast phosphorylates both serine and threonine residues of casein. Identification of the phosphorylation sites. *Biochim Biophys Acta* **829**, 180-187 (1985).
27. Flotow, H. et al. Phosphate groups as substrate determinants for casein kinase I action. *J Biol Chem* **265**, 14264-14269 (1990).
28. Flotow, H. & Roach, P.J. Role of acidic residues as substrate determinants for casein kinase I. *J Biol Chem* **266**, 3724-3727 (1991).
29. Marin, O., Meggio, F. & Pinna, L.A. Design and synthesis of two new peptide substrates for the specific and sensitive monitoring of casein kinases-1 and -2. *Biochem Biophys Res Commun* **198**, 898-905 (1994).
30. Meggio, F., Donella-Deana, A. & Pinna, L.A. Studies on the structural requirements of a microsomal cAMP-independent protein kinase. *FEBS Lett* **106**, 76-80 (1979).

31. Meggio, F., Perich, J.W., Reynolds, E.C. & Pinna, L.A. A synthetic beta-casein phosphopeptide and analogues as model substrates for casein kinase-1, a ubiquitous, phosphate directed protein kinase. *FEBS Lett* **283**, 303-306 (1991).
32. Pulgar, V. et al. Optimal sequences for non-phosphate-directed phosphorylation by protein kinase CK1 (casein kinase-1)--a re-evaluation. *Eur J Biochem* **260**, 520-526 (1999).
33. Umphress, J.L., Tuazon, P.T., Chen, C.J. & Traugh, J.A. Determinants on simian virus 40 large T antigen are important for recognition and phosphorylation by casein kinase I. *Eur J Biochem* **203**, 239-243 (1992).
34. Ha, N.C., Tonzuka, T., Stamos, J.L., Choi, H.J. & Weis, W.I. Mechanism of phosphorylation-dependent binding of APC to beta-catenin and its role in beta-catenin degradation. *Mol Cell* **15**, 511-521 (2004).
35. Marin, O. et al. Structural features underlying the multisite phosphorylation of the A domain of the NF-AT4 transcription factor by protein kinase CK1. *Biochemistry* **41**, 618-627 (2002).
36. Marin, O. et al. A noncanonical sequence phosphorylated by casein kinase 1 in beta-catenin may play a role in casein kinase 1 targeting of important signaling proteins. *Proc Natl Acad Sci U S A* **100**, 10193-10200 (2003).
37. Kawakami, F., Suzuki, K. & Ohtsuki, K. A Novel Consensus Phosphorylation Motif in Sulfatide- and Cholesterol-3-sulfate-Binding Protein Substrates for CK1 in Vitro. *Biological and Pharmaceutical Bulletin* **31**, 193-200 (2008).
38. Holmes, J.K. & Solomon, M.J. A predictive scale for evaluating cyclin-dependent kinase substrates. A comparison of p34cdc2 and p33cdk2. *The Journal of biological chemistry* **271**, 25240-25246 (1996).
39. Rachidi, N. et al. Pharmacological assessment defines the Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection. *Antimicrob Agents Chemother* **58** (2014).
40. Richter, J. et al. CK1alpha overexpression correlates with poor survival in colorectal cancer. *BMC Cancer* **18**, 140 (2018).
41. Zhang, L. et al. The down-regulation of casein kinase 1 alpha as a host defense response against infectious bursal disease virus infection. *Virology* **512**, 211-221 (2017).
42. Bhattacharya, D., Ansari, I.H. & Striker, R. The flaviviral methyltransferase is a substrate of Casein Kinase 1. *Virus research* **141**, 101-104 (2009).
43. Cegielska, A., Moarefi, I., Fanning, E. & Virshup, D.M. T-antigen kinase inhibits simian virus 40 DNA replication by phosphorylation of intact T antigen on serines 120 and 123. *Journal of virology* **68**, 269-275 (1994).
44. Sudha, G., Yamunadevi, S., Tyagi, N., Das, S. & Srinivasan, N. Structural and molecular basis of interaction of HCV non-structural protein 5A with human casein kinase 1alpha and PKR. *BMC structural biology* **12**, 28 (2012).
45. Smirlis, D. et al. SILAC-based quantitative proteomics reveals pleiotropic, phenotypic modulation in primary murine macrophages infected with the protozoan pathogen Leishmania donovani. *Journal of proteomics* **213**, 103617 (2020).
46. Singh, A.K. et al. Proteomic-based approach to gain insight into reprogramming of THP-1 cells exposed to Leishmania donovani over an early temporal window. *Infection and immunity* **83**, 1853-1868 (2015).
47. da Silva Santos, C. et al. Proteome profiling of human cutaneous leishmaniasis lesion. *The Journal of investigative dermatology* **135**, 400-410 (2015).
48. Negrão, F., Diedrich, J.K., Giorgio, S., Eberlin, M.N. & Yates, J.R., 3rd Tandem Mass Tag Proteomic Analysis of in Vitro and in Vivo Models of Cutaneous Leishmaniasis Reveals Parasite-Specific and Nonspecific Modulation of Proteins in the Host. *ACS infectious diseases* **5**, 2136-2147 (2019).
49. Fernandes, M.C. et al. Dual Transcriptome Profiling of *Leishmania*-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. *mBio* **7**, e00027-00016 (2016).
50. Dillon, L.A. et al. Simultaneous transcriptional profiling of Leishmania major and its murine macrophage host cell reveals insights into host-pathogen interactions. *BMC genomics* **16**, 1108 (2015).

51. Frank, B. et al. Autophagic digestion of *Leishmania major* by host macrophages is associated with differential expression of BNIP3, CTSE, and the miRNAs miR-101c, miR-129, and miR-210. *Parasites & vectors* **8**, 404 (2015).
52. Rabhi, I. et al. Comparative analysis of resistant and susceptible macrophage gene expression response to *Leishmania major* parasite. *BMC genomics* **14**, 723 (2013).
53. Moore, K.J. & Matlashewski, G. Intracellular infection by *Leishmania donovani* inhibits macrophage apoptosis. *J Immunol* **152**, 2930-2937 (1994).
54. Gupta, P., Srivastav, S., Saha, S., Das, P.K. & Ukil, A. *Leishmania donovani* inhibits macrophage apoptosis and pro-inflammatory response through AKT-mediated regulation of beta-catenin and FOXO-1. *Cell Death Differ* **23**, 1815-1826 (2016).
55. Osorio y Fortéa, J. et al. Transcriptional signatures of BALB/c mouse macrophages housing multiplying *Leishmania amazonensis* amastigotes. *BMC genomics* **10**, 119 (2009).
56. Shah, K. & Kim, H. The significant others: Global search for direct kinase substrates using chemical approaches. *IUBMB life* **71**, 721-737 (2019).
57. Martel, D. et al. The low complexity regions in the C-terminus are essential for the subcellular localisation of *Leishmania* casein kinase 1 but not for its activity. *bioRxiv*, 2020.2002.2028.969741 (2020).
58. Bouhaddou, M. et al. The Global Phosphorylation Landscape of SARS-CoV-2 Infection. *Cell* **182**, 685-712.e619 (2020).
59. Smirlis, D. et al. SILAC-based quantitative proteomics reveals pleiotropic, phenotypic modulation in primary murine macrophages infected with the protozoan pathogen *Leishmania donovani*. *Journal of proteomics* **213**, 103617 (2020).
60. Cegielska, A. & Virshup, D.M. Control of simian virus 40 DNA replication by the HeLa cell nuclear kinase casein kinase I. *Mol Cell Biol* **13**, 1202-1211 (1993).
61. Jayaswal, S. et al. Identification of host-dependent survival factors for intracellular *Mycobacterium tuberculosis* through an siRNA screen. *PLoS Pathog* **6**, e1000839 (2010).
62. Dacher, M. et al. Probing druggability and biological function of essential proteins in *Leishmania* combining facilitated null mutant and plasmid shuffle analyses. *Mol Microbiol* **93**, 146-166 (2014).
63. Durieu, E. et al. From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using *Leishmania* Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity. *Antimicrob Agents Chemother* **60**, 2822-2833 (2016).
64. Roy, S., Kumar, G.A., Jafurulla, M., Mandal, C. & Chattopadhyay, A. Integrity of the actin cytoskeleton of host macrophages is essential for *Leishmania donovani* infection. *Biochimica et biophysica acta* **1838**, 2011-2018 (2014).
65. Rachidi, N. et al. Pharmacological assessment defines *Leishmania donovani* casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection. *Antimicrobial agents and chemotherapy* **58**, 1501-1515 (2014).
66. Poulet, P., Carpentier, S. & Barillot, E. myProMS, a web server for management and validation of mass spectrometry-based proteomic data. *Proteomics* **7**, 2553-2556 (2007).
67. Perez-Riverol, Y. et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. *Nucleic acids research* **47**, D442-d450 (2019).
68. Hornbeck, P.V. et al. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. *Nucleic acids research* **43**, D512-520 (2015).
69. Vacic, V., Iakoucheva, L.M. & Radivojac, P. Two Sample Logo: a graphical representation of the differences between two sets of sequence alignments. *Bioinformatics* **22**, 1536-1537 (2006).
70. Szklarczyk, D. et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic acids research* **47**, D607-d613 (2019).
71. Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome research* **13**, 2498-2504 (2003).
72. Merico, D., Isserlin, R., Stueker, O., Emili, A. & Bader, G.D. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. *PLoS One* **5**, e13984 (2010).

Table 1. Phosphopeptides

	w/o phosphatase treatment	with phosphatase treatment	Total phospho-sites	%
Total phospho-peptides	99	158	257	
Consensus site for CK1				
Canonical sites	42	84	126	72%
Non-canonical sites	31	43	74	
Others sites	31	46	77	28%
Sites detected in human cell phospho-proteomes				
Site phosphorylated <i>in vivo</i>	92	149	241	94%
SARS-coV2 infection				
Sites phosphorylated during SARS-coV2 infection	20	28	52	20%
Tumorigenesis				
Site phosphorylated in cancer cells	83	146	229	89%
Sites mutated during tumorigenesis	10	16	26	10%

Table 2. Proteins

	w/o phosphatase treatment	with phosphatase treatment	Total proteins	%
Total proteins	81	144	225	
Known human CK1 substrates or binding partners				
Substrates	5	6	11	34
Binding partners	19	47	66	
Leishmania infection				
Proteins differentially regulated during infection	25	47	72	32
Transcripts differentially regulated during infection	20	48	68	30
Tumorigenesis				
Prognosis markers	Favourable	17	23	76
	Unfavourable	34	57	
	Both depending on the cancer type	12	28	
SARS-coV2 infection				
Proteins phosphorylated during infection	37	78	115	51

Table 3. Motifs identified in category ‘others’

Motif	ZScore	P-Value	Foreground Matches	Foreground Size
..G..sP....	8.64	0.00E+00	10	69
..G..s..E..	8.24	0.00E+00	7	69
..G..s.....	6.4	8.02E-11	20	69
.....sP....	9.94	0.00E+00	34	69
.....sD.E..	8.43	0.00E+00	8	69
.....sD....	8.73	0.00E+00	11	69
.....s..E..	5.03	2.43E-07	16	69

FIGURE LEGENDS

Figure 1: Experimental workflow and validation of SILAkin. A.

Upper Panel. Workflow diagram showing the experimental strategy used to reveal L-CK1.2 substratome derived from THP-1 lysates. THP1 cells were cultured and differentiated in the presence of natural amino acids (light, blue) or stable amino acid isotopes (heavy, red). Equal amounts per reaction (0.5 mg) of heavy or light lysates were treated with phosphatase and ATP depleted (*) or not and denatured by heat inactivation to remove endogenous kinase activities. The phosphatase reactions were stopped by heat inactivation. Lysates were then subjected to IVKA in presence of recombinant L-CK1.2 (green), L-CK1.2-K40A (kinase-dead, orange), or were mock treated with equal amounts of kinase elution buffer, in triplicate. The reactions were stopped with heat inactivation and addition of 10 μ M D4476. Lower panel. Equal amounts (0.5 mg) of heavy (L-CK1.2) and light (L-CK1.2-K40A) samples were mixed. In addition, mock heavy and light samples were mixed in a 1:1 ratio and used as a control. The four samples were reduced, alkylated and digested and the resulting phosphopeptides were enriched by TiO₂-affinity chromatography, and processed by LC-MS/MS analysis on Orbitrap fusion. **B.** Sequence logos analysis of unique phospho-sites (five amino acids before and after the phosphorylation residues) matching strict selection criteria. Upper panel, for canonical consensus sites; middle panel, for non-canonical sites; and lower panel, for others. The amino acids are labelled according to their chemical properties: green for polar amino acids (G, S, T, Y, C, Q, N), blue for basic amino acids (K, R, H), red for acidic amino acids (D, E), and black for hydrophobic amino acids (A, V, L, I, P, W, F, M). **C.** Autoradiogram representing IVKA using selected recombinant human

proteins and inactive L-CK1.2-K40A (kinase-dead), active L-CK1.2 alone or in presence of the CK1-specific small molecule inhibitor D4476 (10 μ M). **D.** Autoradiogram representing IVKA using selected recombinant human proteins and recombinant GST-CK1 δ^{TV1} alone or in the presence of D4476.

Figure 2. Protein-protein interaction network of L-CK1.2 substrates.

The dataset was analyzed for protein-protein interactions and visualized using the STRING plugin of the Cytoscape software package. Each node represents a substrate and each edge represents a protein-protein interaction. Round shape represents sites phosphorylated in cancer cells; Diamond shape represents sites not phosphorylated in cancer cells; Red border indicates phospho-sites mutated during tumorigenesis; Green fill color indicates proteins phosphorylated during SARS-Cov2 infection. The labeling indicates the UniProt human name. The size of the node represents the ratio $(\text{Heavy}_{\text{L-CK1.2}}/\text{Light}_{\text{L-CK1.2-K40A}})/(\text{Heavy}/\text{Light mock})$.

Figure 3. L-CK1.2 targets specific pathways.

Functional enrichment analysis of the whole dataset was performed using the g:profiler web server. Results were visualized using the EnrichmentMap plugin of the Cytoscape software package, with a p-value and a Q-value above 0.05 and an edge cut-off of 0.375. Node colour represents the enrichment p-value. Node size is proportional to the total number of genes belonging to the corresponding gene-set. The edge corresponds to the Annotation shared between two nodes (blue), with edge thickness corresponding to the number of shared genes. Node clusters were identified and annotated by the AutoAnnotate plugin of cytoscape. See Table S1 for list of the whole list of annotations.

SUPPLEMENTARY DATA

Figure S1. Increase of accessible residues for *de novo* phosphorylation following phosphatase treatment.

Left panel. Autoradiogram representing IVKA using THP-1 cell extracts treated (lane 3 and 4) or not (lane 1 and 2) with Antarctic phosphatase, and active L-CK1.2 (lane 1 and 3) or inactive L-CK1.2-K40A (lane 2 and 4). Right Panel. Same gel stained with coomassie blue.



Figure S2. Comparison of the different experimental conditions.

Venn diagrams showing the numbers and overlaps of phosphopeptides (A and C) or proteins (B and D) in the following four experiments: Heavy_{L-CK1.2}/Light_{L-CK1.2-K40A} and Heavy/Light mock, treated (A and B) or not with Antarctic phosphatase (C and D).

Figure S3. Common pathways targeted by L-CK1.2 and phosphorylated during SARS-CoV2 infection.

Functional enrichment analysis of the proteins phosphorylated by L-CK1.2 and also during SARS-CoV2 infection was performed using the g:profiler web server. Results were visualized using the EnrichmentMap plugin of the Cytoscape software package, with a p-value and a Q-value above 0.03 and an edge cut-off of 0.375. Node colour represents the enrichment p-value. Node size is proportional to the total number of genes belonging to the corresponding gene-set. The edge corresponds to the Annotation shared between two nodes (blue), with edge thickness corresponding to the number of shared genes. Node clusters were identified and annotated by the AutoAnnotate plugin of cytoscape. See Table 2 (RNA splicing & processing) and 3 (cellular localisation & transport) for the list of annotations.

Figure 1




C





Name	L-CK1.2	L-CK1.2-K40A	Phosphorylation sequence	Corresponding consensus site
14.3.3 γ			M <u>K</u> N <u>V</u> p T E L N	K/R(XX)pS/pT
Glo1			D D E T Q p S Y H N G	[E/D]X ₂₋₃ [pS/pT]
RCN2			D F D E N p T A L D D	[E/D]X ₂₋₃ [pS/pT]
Name	L-CK1.2	L-CK1.2 + D4476		
SNAP23			D G G E N p S P C N V	New consensus site ?
TAF7			V K R L L p S T D A E	K/R(XX)pS/pT

D

substrates	HuCK1d	HuCK1d +D4476
14.3.3		
Glo1		
RCN2		
SNAP23		
TAF7		

Figure 2



-  Sites phosphorylated in cancer cells
-  Sites not phosphorylated in cancer cells
-  Proteins phosphorylated during SARS-CoV2 infection
-  Phospho-sites mutated during tumorigenesis




Figure 3




Figure S1

A






Figure S2



B

	CK1/CK1 dead - With phosphatase (11753)	CK1/CK1 dead - Without phosphatase (6378)	Heavy/Light - Without phosphatase (4960)
Heavy/Light - With phosphatase (11992)	7893	3770	3041
CK1/CK1 dead - With phosphatase (11753)		3858	3085
CK1/CK1 dead - Without phosphatase (6378)			3586



D

	CK1/CK1 dead - With phosphatase (4196)	CK1/CK1 dead - Without phosphatase (3032)	Heavy/Light - Without phosphatase (2750)
Heavy/Light - With phosphatase (4276)	3314	2424	2239
CK1/CK1 dead - With phosphatase (4196)		2379	2198
CK1/CK1 dead - Without phosphatase (3032)			2238

Figure S3




Table S2. List of annotations of proteins targeted by L-CK1.2 and phosphorylated in SARS-CoV2 infection.

RNA splicing & processing		
Gene set name	Gene set description	fdr-qvalue
GO:0008380	RNA splicing	7.56E-06
GO:1903311	regulation of mRNA metabolic process	0.002061234
GO:0000398	mRNA splicing, via spliceosome	2.89E-04
GO:0090304	nucleic acid metabolic process	0.023112918
GO:0031123	RNA 3'-end processing	0.021130162
GO:0016071	mRNA metabolic process	1.13E-06
GO:0000375	RNA splicing, via transesterification reactions	3.16E-04
GO:0006397	mRNA processing	9.25E-07
GO:0050684	regulation of mRNA processing	0.001816144
GO:0031124	mRNA 3'-end processing	0.024329926
GO:0006396	RNA processing	1.05E-06
GO:0000377	RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	2.89E-04
GO:0016070	RNA metabolic process	0.009712339

Table S3. List of annotations of proteins targeted by L-CK1.2 and phosphorylated in SARS-CoV2 infection.

Cellular localisation & transport		
Gene set name	Gene set description	fdr-qvalue
GO:0070727	cellular macromolecule localization	0.033862353
GO:0034613	cellular protein localization	0.03115501
GO:1903827	regulation of cellular protein localization	0.034549815
GO:0046907	intracellular transport	0.01168741
GO:0051168	nuclear export	0.0122513
GO:0051169	nuclear transport	2.56E-04
GO:0006913	nucleocytoplasmic transport	0.014728889

Table S4 List of annotations of L-CK1.2 host substrates

Gene set name	Gene set description	fdr-qvalue
Positive regulation of processes		
GO:0031324	negative regulation of cellular metabolic process	0.02340261
GO:0051254	positive regulation of RNA metabolic process	2.91E-04
GO:0016070	RNA metabolic process	9.47E-04
GO:0045935	positive regulation of nucleobase-containing compound metabolic process	7.26E-04
GO:0010604	positive regulation of macromolecule metabolic process	0.003190292
GO:1902680	positive regulation of RNA biosynthetic process	0.001073438
GO:0045893	positive regulation of transcription, DNA-templated	0.001055616
GO:0009891	positive regulation of biosynthetic process	0.004134998
GO:0009893	positive regulation of metabolic process	0.008312924
GO:0019219	regulation of nucleobase-containing compound metabolic process	0.010585512
GO:0051252	regulation of RNA metabolic process	0.002945695
GO:0031328	positive regulation of cellular biosynthetic process	0.002433485
GO:0031325	positive regulation of cellular metabolic process	2.83E-04
GO:1903508	positive regulation of nucleic acid-templated transcription	0.001055616
GO:0010557	positive regulation of macromolecule biosynthetic process	0.002615297
GO:0051173	positive regulation of nitrogen compound metabolic process	0.003447023
RNA splicing and processing		
GO:0043484	regulation of RNA splicing	0.008004015
GO:0016071	mRNA metabolic process	2.61E-06
GO:0050684	regulation of mRNA processing	1.27E-04
GO:0006396	RNA processing	6.30E-07
GO:1903311	regulation of mRNA metabolic process	2.49E-05
GO:0008380	RNA splicing	2.89E-06
GO:0048024	regulation of mRNA splicing, via spliceosome	0.003665786
GO:0000377	RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	3.15E-05
GO:0000398	mRNA splicing, via spliceosome	3.15E-05
GO:0006397	mRNA processing	2.73E-06
GO:0000375	RNA splicing, via transesterification reactions	3.62E-05
GTPase signal transduction		
GO:0043547	positive regulation of GTPase activity	0.022879605
GO:0044093	positive regulation of molecular function	0.001917564
GO:0065009	regulation of molecular function	7.54E-04
GO:0051056	regulation of small GTPase mediated signal transduction	0.001020463
GO:0035556	intracellular signal transduction	0.020143175
GO:0050790	regulation of catalytic activity	0.014427716
GO:0007264	small GTPase mediated signal transduction	0.002340487
GO:0043085	positive regulation of catalytic activity	0.029701682
GO:0048583	regulation of response to stimulus	0.030720627
Apoptosis & protein localization pathways		
GO:1900739	regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway	0.02742253
GO:0051641	cellular localization	1.52E-06
GO:0046907	intracellular transport	9.95E-05
GO:1903827	regulation of cellular protein localization	0.012139707
GO:0006915	apoptotic process	0.008010955
GO:1900740	positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway	0.02742253
GO:0008219	cell death	0.015430219
GO:0051649	establishment of localization in cell	1.11E-06
Actin cytoskeleton organisation		
GO:0007015	actin filament organization	0.003986568
GO:0030036	actin cytoskeleton organization	0.010148642
GO:0006996	organelle organization	0.045068974
GO:0044085	cellular component biogenesis	0.011134548
GO:0051128	regulation of cellular component organization	0.006282436
GO:0030029	actin filament-based process	0.009912871
Response to environmental stimuli		
GO:0071214	cellular response to abiotic stimulus	0.033084627
GO:0104004	cellular response to environmental stimulus	0.033084627
Viral & symbiotic interactions		
GO:0044403	biological process involved in symbiotic interaction	0.002458985
GO:0016032	viral process	6.70E-04